Recanalization after thrombolysis in stroke patients: Predictors and prognostic implications

Neurology

Volumn 68, Issue 1, 2007, Pages 39-44

  Zangerle, A ^a   Kiechl, S ^a   Spiegel, M ^a   Furtner, M ^a   Knoflach, M ^a   Werner, P ^a   Mair, A ^a   Wille, G ^a   Schmidauer, C ^a   Gautsch, K ^a   Gotwald, T ^a   Felber, S ^a   Poewe, W ^a   Willeit, J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBRAL ARTERY DISEASE; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DATA COLLECTION METHOD; DIABETES MELLITUS; DOPPLER ECHOGRAPHY; DRUG FATALITY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RATING SCALE; RECANALIZATION; RISK FACTOR; STANDARD; STATISTICAL ANALYSIS; STROKE; STROKE PATIENT;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33846045948     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000250341.38014.d2     Document Type: Article

References (29)

1. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
3. Alexandrov AV, Burgin WS, Demchuk AM, El Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation 2001;103:2897-2902.
4. Alexandrov AV, Demchuk AM, Burgin WS, Robinson DJ, Grotta JC. Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial. J Neuroimaging 2004;14:113-117.
5. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170-2178.
6. Christou I, Alexandrov AV, Burgin WS, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke 2000;31:1812-1816.
7. Demchuk AM, Burgin WS, Christou I, et al. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001;32:89-93.
8. Georgiadis D, Oehler J, Schwarz S, Rousson V, Hartmann M, Schwab S. Does acute occlusion of the carotid T invariably have a poor outcome? Neurology 2004;63:22-26.
9. Kwon JH, Kwon SU, Lee JH, Choi CG, Suh DC, Kim JS. Factors affecting the angiographic recanalization and early clinical improvement in middle cerebral artery territory infarction after thrombolysis. Arch Neurol 2004;61:1682-1686.
10. Linfante I, Llinas RH, Selim M, et al. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke 2002;33:2066-2071.
11. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001;32:2821-2827.
12. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabin J. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 2004;35:151-156.
13. Molina CA, Ribo M, Rubiera M, et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 2006;37:425-429.
14. Neumann-Haefelin T, du Mesnil de Rochemond DR, Fiebach JB, et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke 2004;35:109-114.
15. Perren F, Poglia D, Sekoranja L, Loulidi J, Landis T, Sztajzel R. Do transcranial color-coded duplex ultrasound and echo contrast agent use accelerate thrombolysis in acute middle cerebral artery infarction? [abstract]. Cerebrovasc Dis 2005;19(suppl 2):77.
16. Rother J, Schellinger PD, Gass A, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 2002;33:2438-2445.
17. Savitz SI, Schlaug G, Caplan L, Selim M. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke. Stroke 2005;36:1447-1451.
18. Schellinger PD, Chalela JA, Kang DW, Latour LL, Warach S. Diagnostic and prognostic value of early MR. Imaging vessel signs in hyperacute stroke patients imaged <3 hours and treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol 2005;26:618-624.
19. Wunderlich M, Stolz E, Seidel G, et al. Conservative medical treatment and intravenous thrombolysis in acute stroke from carotid t occlusion. Cerebrovasc Dis 2005;20:355-361.
20. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78-86.
21. Burgin WS, Malkoff M, Felberg RA, et al. Transcranial doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke 2000;31:1128-1132.
22. Angeja BG, de Lemos J, Murphy SA, et al. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J 2002;144:649-656.
23. Zairis MN, Lyras AG, Makrygiannis SS, et al. Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction. Diabetes Care 2004;27:967-971.
24. Schneider D, Nordt T, Sobel B. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993;42:1-7.
25. Nicholls SC, Hoffer EK, Chandler W. Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1. Blood Coagul Fibrinolysis 2003;14:729-733.
26. Yanhong Z, Carmeliet P, Fay W. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999;99:3050-3055.
27. Madsen MM, Busk M, Sondergaard HM, et al. Does diabetes mellitus abolish the beneficial effect of primary coronary angioplasty on long-term risk of reinfarction after acute ST-segment elevation myocardial infarction compared with fibrinolysis? (A DANAMI-2 substudy). Am J Cardiol 2005;96:1469-1475.
28. Dudek D, Mielecki W, Legutko J, et al. Percutaneous thrombectomy with the RESCUE system in acute myocardial infarction. Kardiol Pol 2004;61:523-533.
29. Labiche LA, Al Senani F, Wojner AW, Grotta JC, Malkoff M, Alexandrov AV. Is the benefit of early recanalization sustained at 3 months? A prospective cohort study. Stroke 2003;34:695-698.